BR112021023927A2 - Composto, e, composição farmacêutica - Google Patents
Composto, e, composição farmacêuticaInfo
- Publication number
- BR112021023927A2 BR112021023927A2 BR112021023927A BR112021023927A BR112021023927A2 BR 112021023927 A2 BR112021023927 A2 BR 112021023927A2 BR 112021023927 A BR112021023927 A BR 112021023927A BR 112021023927 A BR112021023927 A BR 112021023927A BR 112021023927 A2 BR112021023927 A2 BR 112021023927A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- compound
- same
- provides
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
composto, e, composição farmacêutica. a presente invenção provê: um composto tendo efeitos inibitórios de keap1; e uma composição farmacêutica que contém o mesmo. especificamente, a presente invenção provê: um composto representado pela fórmula geral (i) [na fórmula, os símbolos têm os mesmos significados que aqueles descritos no relatório descritivo] ou um sal farmaceuticamente aceitável do mesmo; e uma composição farmacêutica que contém o mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019102529 | 2019-05-31 | ||
PCT/JP2020/021426 WO2020241853A1 (ja) | 2019-05-31 | 2020-05-29 | ベンゾトリアゾール誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021023927A2 true BR112021023927A2 (pt) | 2022-02-08 |
Family
ID=73553193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021023927A BR112021023927A2 (pt) | 2019-05-31 | 2020-05-29 | Composto, e, composição farmacêutica |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220259223A1 (pt) |
EP (1) | EP3978073A4 (pt) |
JP (1) | JPWO2020241853A1 (pt) |
KR (1) | KR20220016124A (pt) |
CN (1) | CN114174289A (pt) |
AU (1) | AU2020283361A1 (pt) |
BR (1) | BR112021023927A2 (pt) |
CA (1) | CA3142295A1 (pt) |
MX (1) | MX2021014680A (pt) |
WO (1) | WO2020241853A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019326368B2 (en) | 2018-08-20 | 2021-11-11 | Janssen Pharmaceutica Nv | Inhibitors of KEAP1-Nrf2 protein-protein interaction |
CN113024399B (zh) * | 2021-03-11 | 2022-09-09 | 华东理工大学 | 药物中间体化合物及其制备方法、应用 |
TW202404984A (zh) * | 2022-04-28 | 2024-02-01 | 日商第一三共股份有限公司 | 苯并***化合物 |
TW202345792A (zh) * | 2022-04-28 | 2023-12-01 | 日商第一三共股份有限公司 | 苯并噻吩化合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015092713A1 (en) | 2013-12-18 | 2015-06-25 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
WO2016203400A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
EP3359532A1 (en) | 2015-10-06 | 2018-08-15 | GlaxoSmithKline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
JP2020500919A (ja) | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーターとしての3−カルボン酸ピロール |
EP3551621A1 (en) | 2016-12-12 | 2019-10-16 | GlaxoSmithKline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのビスアリール複素環 |
WO2018109648A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
EP3555104B1 (en) | 2016-12-15 | 2021-11-24 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 compounds |
US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
WO2019116231A1 (en) * | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
US11643407B2 (en) | 2018-05-23 | 2023-05-09 | Glaxosmithkline Intellectual Property Development Limited | Indanes as NRF2 activators |
AU2019326368B2 (en) | 2018-08-20 | 2021-11-11 | Janssen Pharmaceutica Nv | Inhibitors of KEAP1-Nrf2 protein-protein interaction |
-
2020
- 2020-05-29 EP EP20815167.0A patent/EP3978073A4/en active Pending
- 2020-05-29 US US17/614,941 patent/US20220259223A1/en active Pending
- 2020-05-29 WO PCT/JP2020/021426 patent/WO2020241853A1/ja unknown
- 2020-05-29 JP JP2021522912A patent/JPWO2020241853A1/ja active Pending
- 2020-05-29 KR KR1020217042003A patent/KR20220016124A/ko unknown
- 2020-05-29 MX MX2021014680A patent/MX2021014680A/es unknown
- 2020-05-29 CN CN202080055155.9A patent/CN114174289A/zh active Pending
- 2020-05-29 BR BR112021023927A patent/BR112021023927A2/pt unknown
- 2020-05-29 AU AU2020283361A patent/AU2020283361A1/en active Pending
- 2020-05-29 CA CA3142295A patent/CA3142295A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3978073A4 (en) | 2023-07-12 |
JPWO2020241853A1 (pt) | 2020-12-03 |
KR20220016124A (ko) | 2022-02-08 |
AU2020283361A1 (en) | 2022-01-20 |
US20220259223A1 (en) | 2022-08-18 |
CN114174289A (zh) | 2022-03-11 |
EP3978073A1 (en) | 2022-04-06 |
CA3142295A1 (en) | 2020-12-03 |
WO2020241853A1 (ja) | 2020-12-03 |
MX2021014680A (es) | 2022-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
WO2019191229A8 (en) | Compounds for treating huntington's disease | |
UY38186A (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
WO2018226622A8 (en) | Compounds for treating huntington's disease | |
BR112018071093A2 (pt) | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo | |
WO2017100726A8 (en) | Methods for treating huntington's disease | |
BR112018070859A2 (pt) | degradantes da proteína de bet | |
BR112016003348A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
BR112019024785A2 (pt) | composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
MX2021013854A (es) | Compuestos para tratar enfermedad de huntington. | |
BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR112019016291A2 (pt) | novo composto heterocíclico, seu método de preparação e composição farmacêutica compreendendo o mesmo | |
BR112020016020A8 (pt) | Inibidor de atr e aplicação do mesmo | |
BR112022025613A2 (pt) | Novo inibidor de secreção de ácido e uso do mesmo | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
BR112023006761A2 (pt) | Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: UBE CORPORATION (JP) |